Coya Therapeutics, Inc. (COYA): Cash & Equivalents
$46.82M
As of 2025-12-31
$43.18M
As of 2026-06-30
+99.1%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $46.82M | +22.1% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $38.34M | +17.5% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $32.63M | +449.9% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $5.93M | +36.7% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $4.34M | n/a | 2023-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $19.96M | -18.8% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $11.70M | +62.4% |
| Adagene Inc. (ADAG) | 2025-12-31 | $74.52M | -12.5% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $1.42B | -47.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $199.16M | +39.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $37.57M | +31.0% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $188.89M | -46.7% |
Compare COYA, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗